Drugs / CT048
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05393986 | Aug 2022 → Jun 2023 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, malignant pancreatic neoplasm | Peking University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT048 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05393986 ↗ |
| Modality | Cell therapy | “CAR-CLDN18.2 T-Cells (CT048)” NCT05393986 ↗ |